November 5, 2023
Runners will take on the marathon to support CMT research.
If you are interested in participating please email [email protected].
treatment with ACE-083 in patients with Charcot-Marie-Tooth disease (CMT) did not demonstrate functional improvement in the Phase 2 trial
Welcome and Opening Remarks Overview: What is CMT? - Michael Shy, MD Overview: What is CMT? - Dr....
HNF successfully executed the Externally-led PFDD Meeting for the FDA on September 28th, 2018.
HNF will be holding a landmark externally-led Patient-Focused Drug Development Meeting for CMT and INs in Washington, D.C. on Friday, September 28, 2018.
2018 will be “the year” for our community as we prepare for the externally-led Patient-Focused Drug Development Meeting.
Help support this ground-breaking PFDD CMT Meeting being held on September 28, 2018 in Washington, D.C.
HNF will be holding a landmark externally-led Patient-Focused Drug Development (PFDD) Meeting CMT & INs in Washington, D.C. on September 28, 2018. The meeting will be held in conjunction with September National CMT Awareness Month.
Pharnext completed patient enrollment for the international Phase 3 clinical trial of PXT3003, Pharnext’s lead PLEODRUG ©, for treatment of CMT1A.
For the first time investigators are looking for patients to participate in a pivotal Phase 3 clinical trial of Pharnext’s lead investigational pleodrug, PXT-3003 for the potential treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).
French pharmaceutical company Pharnext announced the opening of the first U.S. trial site for its PLEO-CMT pivotal Phase 3 clinical trial of its lead pleodrug PXT-3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A).
0 Comments